Opendata, web and dolomites

MagnoBeads

Removing endotoxins during sepsis: a blood purification platform using magnetic nanoparticles

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MagnoBeads project word cloud

Explore the words cloud of the MagnoBeads project. It provides you a very rough idea of what is the project "MagnoBeads" about.

excellent    filter    authorization    designed    spin    tested    2026    foundation    financially    magnetic    upscaling    19    blood    molecules    huge    clinical    eth    septic    off    ready    company    prototype    treat    regulatory    million    relieving    cure    mortality    removes    small    exists    dialysis    zurich    models    engineering    position    delivering    proprietary    market    responsible    strategies    2017    symptoms    swiss    trials    hemotune    receive    platform    treatment    care    operate    sepsis    ongoing    commercial    founded    put    nanoparticles    commercialize    capitalize    selectively    feasibility    commercialization    halted    stabilizing    intensive    subsequently    uuml    death    employs       strategy    gebert    endotoxins    device    successfully    filtered    sized    nanoparticle    financial    human    move    ip    opportunity    usability    treatments    freedom    purification    academic    curative    composition    combined    solid    entails    uniquely    rate    animal    evaluation    smei    people    patient    billion    30    wyss    units    capture    removing   

Project "MagnoBeads" data sheet

The following table provides information about the project.

Coordinator
HEMOTUNE AG 

Organization address
address: C/O ETH ZURICH WEINBERGSTRASSE 35 WEH F14
city: ZURICH
postcode: 8092
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.hemotune.ch
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HEMOTUNE AG CH (ZURICH) coordinator 50˙000.00

Map

 Project objective

Hemotune is a Swiss academic spin-off company founded in 2017 to commercialize proprietary blood purification technology using uniquely designed magnetic nanoparticles, developed at ETH Zürich. Hemotune is financially supported by Wyss Zurich and the Gebert Rüf foundation to develop a product to treat sepsis. Sepsis affects 19 million people each year, and with a mortality rate of 30% it is the most common cause of death in intensive care units. Currently, no cure for sepsis exists, and treatment focuses on relieving symptoms. Therefore, a huge market opportunity exists for curative sepsis treatments, which is estimated to reach €4.3 billion by 2026.

Using its proprietary blood purification technology, hemotune aims to capitalize on this market opportunity by developing a dialysis-like device that removes endotoxins (molecules responsible for sepsis) from the blood. This device employs magnetic nanoparticles to selectively capture endotoxins, which are subsequently filtered out of the blood by a magnetic filter. By removing these endotoxins, the septic response is halted, stabilizing the patient. This technology was successfully tested in small-scale animal models, and now R&D activities will focus on developing a human-sized prototype product, ready for clinical evaluation.

Financial support from the SMEi phase 1 will be used to assess the technical and commercial feasibility of the nanoparticle-based blood purification platform as a treatment strategy for sepsis. Technical feasibility includes usability engineering, and feasibility studies into the upscaling, and into regulatory feasibility to receive market authorization. Commercial feasibility entails a freedom to operate analysis, and composition of solid IP and commercialization strategies. This SMEi phase 1 feasibility study, combined with the ongoing R&D delivering the prototype product, put hemotune in an excellent position to rapidly move forward towards clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGNOBEADS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGNOBEADS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

MACCO (2019)

Bring social robots into reality with the first real world leading bartender (MACCO)

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More